Home Infusion Therapy Market Report, Size | Industry Analysis, 2030
The global Home Infusion Therapy market size was estimated at USD 43.4 billion in 2021 and is expected to surpass around USD 65.2 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 4.63% during the forecast period 2022 to 2030.
Key Takeaways:
Home infusion therapy refers to the process in which patients receive treatment at home through the administration of drugs or biologicals through catheters and needles. Receiving treatment at home as opposed to hospitals or healthcare facilities is a cost-effective and more convenient option for patients, further driving the need for home infusion therapy.
Home infusion therapy involves the intravenous or subcutaneous administration of drugs or biologicals to an individual at home. Favorable government policies and regulations are expected to propel market growth. In February 2018, the Bipartisan Budget Act of 2018 was signed into a law that states that all temporary payments of home infusion therapy in the U.S. will be covered by the government in accordance with this regulation.
In addition, the rising prevalence of chronic diseases, such as cardiovascular diseases (CVDs), cancer, diabetes, and other life-threatening conditions, is expected to have a high impact on the market growth. According to a WHO report, the above-mentioned diseases accounted for 60.0% of the total deaths and 43.0% of the disease burden in the U.S. in 2019. This creates the need to infuse nutritional products that contain glutamine, phospholipids, glucose, and amino acids while administering medication to patients, which, in turn, is expected to boost the market growth in this region.
The ongoing COVID-19 pandemic is expected to create lucrative opportunities for the market. Due to the restrictions caused by COVID-19, patients are waiting to seek treatment until they feel safe. Moreover, patients who seek infusion therapy already have diseases, which eventually weaken their immune systems. In such cases, going outside even to receive treatment becomes a potential threat. Reduced operating hours have led to difficulty in scheduling appointments as well, even if patients choose to continue treatment. Hence, home infusion therapy is expected to play a key role in supporting patients.
Report Scope of the Home Infusion Therapy Market
|
Report Coverage |
Details |
|
Market Size in 2022 |
USD 45.41 Billion |
|
Market Size by 2030 |
USD 65.2 Billion |
|
Growth Rate from 2022 to 2030 |
CAGR of 4.63% |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Product, Application, Route of Administration, End User, Geography |
|
Companies Mentioned |
CVS/Coram, Option Care Health, BriovaRx/Diplomat (UnitedHealth Optum, PharMerica, Fresenius Kabi, ICU Medical, Inc., B. Braun Melsungen AG, Baxter, BD, Caesarea Medical Electronics, Smith’s Medical, Terumo Corporation, JMS Co. Ltd., Others |
Product Insights
The infusion pumps segment accounted for the largest revenue share of over 50.4% in 2021 as these pumps are widely preferred for the delivery of nutrients and medications. On the basis of product, the market for home infusion therapy is segmented into infusion pumps, ambulatory infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The availability of a variety of products such as enteral, syringe, multichannel, and peristaltic pumps further contributes to the segment growth. The rising demand for syringes and ambulatory pumps owing to the increasing preference for home healthcare is also anticipated to contribute to the segment growth.
Nowadays, smart pumps are widely used as these pumps contain advanced features such as barcode technology, which helps in the verification of a patient’s identity and prevents drug administration errors. Needleless connectors are anticipated to register the highest CAGR over the forecast period. These connectors offer improved safety, enable smooth surgeries, and help adhere to good clinical practice (GCP), which contributes to the growth of the segment.
Application Insights
The anti-infective segment dominated the market for home infusion therapy in 2021 with a revenue share of over 25.5%. On the basis of application, the market has been segmented into anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, and specialty pharmaceuticals. This is attributed to the considerable number of procedures performed for the administration of antifungal and antibiotic drugs. It also helps reduce exposure to patients with other hospital-acquired infections (HAIs).
Chemotherapy is estimated to be the fastest-growing segment over the forecast period. With the growing incidences of cancer, the demand for pressure pumps is expected to increase in the coming years. Pumps used for chemotherapy at home are compact, continuous pressure pumps that do not require a battery and can hence be used for a longer period of time. With the help of these pumps, chemotherapy drugs can be administered at the appropriate infusion speed and in the right amounts.
Regional Insights
North America dominated the market in 2021 with a revenue share of over 56% and this trend is expected to continue throughout the forecast period. This can be attributed to the increasing R&D in the region and the rising adoption of new technology in infusion pumps. The increasing need for long-term therapy for patients with certain conditions is driving the regional market. Development of alternate healthcare settings and home infusion services and shifting preference from acute care to home care settings due to the low cost and enhanced patient mobility would boost the growth of this market in the coming years.
The Asia Pacific market is expected to register the fastest CAGR of 9.7% over the forecast period. This is attributed to rising patient awareness regarding the benefits of home infusion therapy over in-hospital procedures and the growing prevalence of diabetes in the region. The growing geriatric population and the rise in chronic diseases in the region are expected to further fuel the market growth. According to the Times of India, around 75 million people over the age of 60 years suffer from some chronic disease in India, which might increase the adoption of home care services in the country.
Some of the prominent players in the Home Infusion Therapy Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Home Infusion Therapy market
By Product
By Application
By Route of Administration
By End User
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Home Infusion Therapy Market
5.1. COVID-19 Landscape: Home Infusion Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Home Infusion Therapy Market, By Product
8.1. Home Infusion Therapy Market, by Product, 2022-2030
8.1.1. Infusion Pumps
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Intravenous Sets
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. IV Cannulas
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Needleless Connectors
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Home Infusion Therapy Market, By Application
9.1. Home Infusion Therapy Market, by Application e, 2022-2030
9.1.1. Anti-infective
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Endocrinology
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hydration Therapy
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Chemotherapy
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Enteral Nutrition
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Parenteral Nutrition
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Specialty Pharmaceuticals
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Home Infusion Therapy Market, By Route of Administration
10.1. Home Infusion Therapy Market, by Route of Administration, 2022-2030
10.1.1. Intramuscular
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Subcutaneously
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Epidural
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Home Infusion Therapy Market, By Route of Administration
11.1. Home Infusion Therapy Market, by Route of Administration, 2022-2030
11.1.1. Patients
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Nurse
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Home Infusion Therapy Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)
Chapter 13. Company Profiles
13.1. CVS/Coram
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Option Care Health
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. BriovaRx/Diplomat (UnitedHealth Optum)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. PharMerica
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Fresenius Kabi
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. ICU Medical, Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. B. Braun Melsungen AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Baxter
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. BD
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Caesarea Medical Electronics
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers